BRIEF-Dermira Says Initiation Of First Phase 3 Clinical Study In Lebrikizumab Phase 3 Development Program Triggers A $7.5 Mln Milestone Payment By Almirall [Reuters]
Journey Medical Corporation (DERM)
Last journey medical corporation earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.dermira.com
Company Research
Source: Reuters
BRIEF-Dermira Says Initiation Of First Phase 3 Clinical Study In Lebrikizumab Phase 3 Development Program Triggers A $7.5 Mln Milestone Payment By Almirall - Reuters 1 Min Read Oct 9 (Reuters) - Dermira Inc: * DERMIRA - INITIATION OF FIRST PHASE 3 CLINICAL STUDY IN LEBRIKIZUMAB PHASE 3 DEVELOPMENT PROGRAM TRIGGERS A $7.5 MILLION MILESTONE PAYMENT BY ALMIRALL * DERMIRA - INITIATION OF LEBRIKIZUMAB PHASE 3 CLINICAL STUDY ALSO TRIGGERS A $20.0 MILLION MILESTONE PAYMENT BY DERMIRA TO F. HOFFMANN-LA ROCHE LTD Source text: ( bit.ly/2ICZUvg ) Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2019 Reuters. All Rights Reserved. BRIEF-Dermira Says Initiation Of First Phase 3 Clinical Study In Lebrikizumab Phase 3 Development Program Triggers A $7.5 Mln Milestone Payment By Almirall Oct 9 (Reuters) - Dermira Inc: * DERMIRA - INITIATION OF FIRST PHASE 3 CLINICAL STUDY IN LEBRIKIZUMAB PHASE 3 DEVELOPMENT PROGRAM
Show less
Read more
Impact Snapshot
Event Time:
DERM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DERM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DERM alerts
High impacting Journey Medical Corporation news events
Weekly update
A roundup of the hottest topics
DERM
News
- Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024GlobeNewswire
- Journey Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerGlobeNewswire
- Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 [Yahoo! Finance]Yahoo! Finance
- Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024GlobeNewswire
- Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
DERM
Earnings
- 11/7/23 - Beat
DERM
Sec Filings
- 5/1/24 - Form 8-K
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- DERM's page on the SEC website